Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Y-mAbs Therapeutics, Inc. | ymab-20201231xex32d2.htm |
| EX-32.1 - EX-32.1 - Y-mAbs Therapeutics, Inc. | ymab-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - Y-mAbs Therapeutics, Inc. | ymab-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Y-mAbs Therapeutics, Inc. | ymab-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - Y-mAbs Therapeutics, Inc. | ymab-20201231xex21d1.htm |
| EX-4.4 - EX-4.4 - Y-mAbs Therapeutics, Inc. | ymab-20201231xex4d4.htm |
| 10-K - 10-K - Y-mAbs Therapeutics, Inc. | ymab-20201231x10k.htm |
EXHIBIT 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-230455) and Form S-3 (No. 333-234034) of Y-mAbs Therapeutics, Inc. of our report dated March 1, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
March 1, 2021